Sanuwave Health reports 35% revenue surge in 2025 with record UltraMist sales

Sanuwave Health has reported strong financial growth for 2025, with revenue and profitability rising sharply. The company's annual revenue climbed by 35%, reaching $44.1 million. Fourth-quarter results also showed significant gains, including a near 30% jump in sales compared to the same period in 2024. For the full year, Sanuwave's revenue hit $44.1 million, up from $32.7 million in 2024. Adjusted EBITDA improved by $6.5 million, landing at $13.6 million. The company sold 624 UltraMist systems in 2025, a notable increase from 374 units the previous year.

Fourth-quarter performance was equally strong. Revenue for Q4 2025 reached $13.4 million, a 29.7% rise from the same quarter in 2024. Adjusted EBITDA for the period grew by $1.1 million to $4.8 million, while operating income remained steady at $2.0 million after accounting for one-time costs. However, gross margin dipped to 74.7%, down from 77.9% in Q4 2024, due to a product line write-off. Net income for the quarter surged to $7.7 million, largely because of changes in derivative liabilities. UltraMist consumables revenue also grew, rising 10.6% to $6.5 million. The company sold 255 UltraMist systems in Q4 alone, nearly doubling the 135 units sold in Q4 2024.

Sanuwave's 2025 results highlight substantial revenue and profit growth, driven by higher sales of UltraMist systems and consumables. The company's financial improvements reflect stronger demand and operational efficiency, despite a slight decline in gross margin. No updates were provided on market position changes or new competitors in the mobile wound care sector.